| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Mug1 |
| Uniprot No | P28665 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 700-910aa |
| 氨基酸序列 | TPEISWSLRTTLSKRPEEPPRKDPSSNDPLTETIRKYFPETWVWDIVTVNSTGLAEVEMTVPDTITEWKAGALCLSNDTGLGLSSVVPLQAFKPFFVEVSLPYSVVRGEAFMLKATVMNYLPTSMQMSVQLEASPDFTAVPVGDDQDSYCLSANGRHTSSWLVTPKSLGNVNFSVSAEAQQSSEPCGSEVATVPETGRKDTVVKVLIVEPE |
| 预测分子量 | 27.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Mug1重组蛋白的参考文献示例(注：以下内容为模拟示例，实际引用请核实原文)：
---
1. **标题**: *Cloning and expression of recombinant Mug1 in Yersinia enterocolitica for protease inhibition studies*
**作者**: Smith J, et al.
**摘要**: 研究报道了在小肠结肠炎耶尔森菌中克隆表达Mug1重组蛋白，证实其作为丝氨酸蛋白酶抑制剂的活性，可能用于抗炎治疗。
2. **标题**: *Structural and functional analysis of Murinoglobulin-1 in renal disease models*
**作者**: Tanaka K, et al.
**摘要**: 通过重组技术在小鼠细胞中表达Mug1.解析其三维结构并验证其在肾脏疾病中抑制蛋白酶活性的保护机制。
3. **标题**: *Recombinant Mug1 as a metal-binding protein: Implications for detoxification pathways*
**作者**: Lee H, et al.
**摘要**: 探讨重组Mug1蛋白的金属离子结合能力，揭示其在细胞解毒和重金属清除中的潜在应用。
4. **标题**: *Therapeutic potential of recombinant Mug1 in chronic kidney injury*
**作者**: Wang Y, et al.
**摘要**: 评估重组Mug1在慢性肾病模型中的治疗效果，显示其通过抑制蛋白酶活性减缓肾纤维化进展。
---
**注意**：以上文献信息为假设性示例，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。
Mug1 (Murine uromodulin) is a glycoprotein predominantly expressed in the thick ascending limb of the kidney epithelium in mice, homologous to human uromodulin (UMOD). It is secreted into urine and plays critical roles in renal physiology, including ion transport regulation, innate immunity, and protection against urinary tract infections. Structurally, Mug1 contains three epidermal growth factor (EGF)-like domains, a zona pellucida (ZP) domain, and multiple glycosylation sites, which contribute to its polymerization and gel-forming properties in urine.
Recombinant Mug1 protein is generated using biotechnological platforms (e.g., mammalian expression systems like HEK293 or CHO cells) to produce functional, post-translationally modified protein for research. Its recombinant form enables detailed studies of its molecular interactions, such as binding to Toll-like receptor 4 (TLR4) to modulate inflammatory responses or its role in regulating renal sodium and calcium transport pathways. Additionally, recombinant Mug1 serves as a tool to investigate uromodulin-associated kidney diseases, including autosomal dominant tubulointerstitial kidney disease (ADTKD-UMOD), where UMOD mutations cause protein aggregation and tubular dysfunction.
Research on Mug1 also explores its potential as a biomarker for chronic kidney disease (CKD) progression, given its correlation with glomerular filtration rate. Furthermore, recombinant Mug1 aids in deciphering mechanisms underlying kidney stone formation, as native uromodulin inhibits calcium crystallization in urine. Its immunomodulatory properties are of interest for therapeutic development, particularly in sepsis or autoimmune conditions. Overall, recombinant Mug1 bridges basic science and clinical applications, offering insights into renal pathophysiology and targeted treatment strategies.
×
